Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).
- Mechanism
- Curator reviewed · 3 references
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
- Primary indication
- Ipilimumab is indicated in the following cancerous conditions: Melanoma Treatment of unresectable or metastatic melanoma in adult and pediatric patients ≥12 years old, alone or in combination with nivolumab Adjuvant treatment of patients with cutaneous...Curator reviewed · 33 structured indications
- Formula / weight
- C6572H10126N1734O2080S40 · 148000.0 Da
- First approval
- Canada, 2012 · United States, 2011 · European Union, 2020
- Code names
- BMS-734016 · CS1002 · HLX13 · IBI-310 · MDX-010 · MDX-101 · MDX-CTLA-4 · MOAB-CTLA-4
- Brand names
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Ipilimumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account